Wednesday, 13 Dec 2017

You are here

The RheumNow Week in Review – 28 July 2017

Dr. Jack Cush reviews the news and articles from the past week on RheumNow.com:

  1. Biologics makes for ~90% of cost of RA care - infusions cost/Yr RTX $36,663; TCZ $36,821, INFLX $4,973; ABA $46,532 https://t.co/HJNaVh4A5m
  2. EU/EMA follows FDA decision to approve Orencia (abatacept) for use in active psoriatic arthritis as mono or combo Rx https://t.co/RkxRsGKahQ
  3. NIH/NIAID phase I & II trial of MV-CHIKV, a recombinant, live-attenuated measles vax expressing chikungunya proteins https://t.co/UjAQelwz8r
  4. Retrospective study 1171 ANCA+ vasculitis shows 16% w/ inflamm ocular disease – Half with eye pain, 16% visuall loss: Scleritis 22% episcleritis 21%, Uveitis 9%  https://t.co/qqrXgaLkBf
  5. RCT shows ustekinumab or guselkumab does NOT significantly reduce the signs and symptoms of RA. https://t.co/14N8ZsKbZ3
  6. Discrepancy between ultrasound and DECT quantification of urate tophi in gout joints; lower sensitivity with DECT https://t.co/RL5Vkq6GSz
  7. Samsung Bioepis launches U.S. sales of Remicade biosmiliar- Renflexis https://t.co/emo6Te0yyW
  8. Biosimilar Pricing Wars Have Begun  
  9. Baricitinib Derailed by FDA Review
  10. Benlysta FDA Approved for Sub-Q Use in Lupus 
  11. Increased Pulmonary Embolism Risk in Lupus Patients  

 

 

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

The RheumNow Week in Review - 8 December 2017

Dr. Jack Cush covers the news and journal articles published on RheumNow.comin the past week.

Rheumatology Year in Review

During 2017, the improvements and refinements seen during previous years in the treatment of rheumatoid arthritis have been extending to other conditions ranging from psoriatic arthritis to lupus and for both monoclonal antibodies and oral small molecule medications.

Advances for Biologics

The ACR17 RheumNow Week in Review - 1 December 2017

Dr Jack Cush reviews nighlights and news from the past 2 weeks on RheumNow.com. This week's report includes new drug approvals, disappointing ACR guidelines, Lyme & Zika, infertility, dermatomyositis skin outcomes and myositis-associated cancer testing.

ACR Clinical Guidelines Flawed by Low Evidence

JAMA Internal Medicine has reported that recommendations and clinical practice guidelines from the American College of Rheumatology are often based on expert opinion, but lack rigorous (grade A) evidence to support many of their recommendations. 

RheumNow ACR 2017 Awards

The Annual Meeting of the American College of Rheumatology is a gargantuan educational and professional event that is on nearly everyone's radar each year. RheumNow had an expansive effort to cover this meeting and you can review the work of our faculty at ACR17.RheumNow.com.  But we have decided to take this one step further and today we are announcing our 2017 RheumNow ACR Awards.